BASF Heads Into Capital Markets Day With Growth Story Under the Microscope
Published on 11/19/2026 at 09:01 | Editorial boerse-global.deBASF has spent the past two weeks buying back its own stock, lining up a divestment and pushing a new soybean trait toward market — yet none of that has shifted the central question hanging over the shares: can the chemicals giant demonstrate that its strategic pipeline translates into hard earnings?
The Ludwigshafen-based group repurchased roughly 8.54 million of its own shares between 3 August and 13 November, it said Monday, with about 591,000 of those bought during the 9–13 November window alone. Investors, however, were focused elsewhere. The stock slipped 1.6% to €51.30, extending the pressure that followed Jefferies' downgrade on 11 November from "Hold" to "Underperform," with the price target held at €44.
Analyst Priyanka Patel pinned the cut on thinning margins, persistent overcapacity, higher gas prices and a demand recovery that has yet to materialise. Her forecast puts 2027 operating profit 5% below consensus — an estimate rather than a reported figure, but one that frames the debate ahead of the 24 November capital markets day, where management will need to show why earnings can improve despite those drags.
A Political Roadblock on the Evonik Track
The growth narrative BASF is trying to build runs alongside a far thornier proposition: a fresh attempt to acquire Evonik. Reuters reported that BASF has sketched out possible additional commitments on sites, jobs and apprenticeships to the North Rhine-Westphalia state government and the RAG Foundation, though no new offer has been confirmed.
Those overtures met a blunt response. Minister President Hendrik Wüst came out against a BASF takeover of Evonik, telling the Süddeutsche Zeitung that the industrial core of North Rhine-Westphalia should be preserved — a stance Reuters described as "very, very skeptical." Two people familiar with Evonik added that a higher bid alone would not secure a deal; a convincing industrial rationale is needed too.
Should investors sell immediately? Or is it worth buying BASF?
For shareholders, the risk is that the takeover debate absorbs attention while the operating pressures flagged by Jefferies persist. Scale on its own would not repair weak margins, and treating a merger's potential benefits as a guaranteed earnings uplift would be premature.
Nemasphere and the Mining Sale as Standalone Levers
Against that backdrop, BASF's own projects offer an alternative case. On Monday the company advanced the global marketing of its Nemasphere technology, with soybean varieties carrying the trait slated to launch in the US and Brazil from 2028. BASF puts peak sales potential at more than €300 million.
That figure is a target, not realised revenue, and it does not yet translate into a concrete earnings contribution. Separately, BASF signed an agreement on 12 November to sell its global mining business to SNF, with completion expected in 2027 subject to regulatory approvals and customary conditions. Financial terms were not disclosed.
The two moves illustrate different levers — one organic, one portfolio — and their value to investors will hinge on whether BASF can tie them into a clear prioritisation of its businesses and their earnings contributions.
What the Capital Markets Day Must Deliver
The decisive test on 24 November is whether BASF can bridge strategy and results. A positive scenario remains plausible without a successful Evonik deal, provided the company can underwrite its standalone growth projects with credible earnings assumptions — the economic contribution matters more than the number of projects on the slide.
Should margin pressure entrench and demand stay muted, the more cautious case gains ground, and long-term sales opportunities would only partly offset nearer-term earnings skepticism. A valuation that already assumes a completed Evonik acquisition looks hard to justify; an earnings outlook that holds up without one would say far more.
Ad
BASF Stock: New Analysis - 19 November
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
